ABSTRACT
Pulmonary hypertension (PH) can be diagnosed in the context of connective tissue diseases (CTD) as well as in elderly patients with multiple comorbidities. A correct clinical differential diagnosis and classification is essential before adequate therapeutic decisions can be made. Differential diagnosis of PH in CTD comprises associated pulmonary arterial hypertension (APAH), group 2 or 3 PH (PH arising from left heart or chronic lung disease), chronic thromboembolic PH (PH) and group 5 (e.âg. in the context of terminal renal insufficiency). This is also true of elderly patients in whom the decision has to be made if the increasing number of coincident diseases lead to PH or have to be interpreted as comorbidities. In this manuscript, the differential diagnosis of PH is elucidated, focusing on CTD, in the context of left heart disease and chronic lung disease. Furthermore, criteria are presented facilitating an objective approach in this context.
Subject(s)
Diagnosis, Differential , Heart Diseases , Hypertension, Pulmonary , Lung Diseases/diagnosis , Connective Tissue Diseases/complications , Connective Tissue Diseases/diagnosis , Heart Diseases/diagnosis , Humans , Hypertension, Pulmonary/diagnosisABSTRACT
At the 6th World Symposium on Pulmonary Hypertension (WSPH), which took place from February 27 until March 1, 2018 in Nice, scientific progress over the past 5 years in the field of pulmonary hypertension (PH) was presented by 13 working groups. The results of the discussion were published as proceedings towards the end of 2018.âOne of the major changes suggested by the WSPH was the lowering of the diagnostic threshold for PH from ≥â25 to >â20âmmHg mean pulmonary arterial pressure, measured by right heart catheterization at rest. In addition, the pulmonary vascular resistance was introduced into the definition of PH, which underlines the importance of cardiac output determination at the diagnostic right heart catheterization.In this article, we discuss the rationale and possible consequences of a changed PH definition in the context of the current literature. Further, we provide a current overview on non-invasive and invasive methods for diagnosis, differential diagnosis, and prognosis of PH, including exercise tests.
Subject(s)
Hypertension, Pulmonary/diagnosis , Hypertension, Pulmonary/therapy , Practice Guidelines as Topic/standards , Cardiac Catheterization , HumansSubject(s)
Embolism, Air/etiology , Image-Guided Biopsy/adverse effects , Intracranial Embolism/diagnosis , Intracranial Embolism/etiology , Lung Neoplasms/pathology , Radiography, Interventional/adverse effects , Aged , Diagnosis, Differential , Embolism, Air/diagnosis , Embolism, Air/therapy , Humans , Intracranial Embolism/therapy , Male , Treatment OutcomeABSTRACT
The 2015 European Guidelines on Diagnosis and Treatment of Pulmonary Hypertension are also valid for Germany. The guidelines contain detailed information about the clinical classification and diagnosis of pulmonary hypertension, and furthermore provide novel recommendations for risk stratification and follow-up assessments. However, the practical implementation of the European Guidelines in Germany requires the consideration of several country-specific issues and already existing novel data. This requires a detailed commentary to the guidelines, and in some aspects an update already appears necessary. In June 2016, a Consensus Conference organized by the PH working groups of the German Society of Cardiology (DGK), the German Society of Respiratory Medicine (DGP) and the German Society of Pediatric Cardiology (DGPK) was held in Cologne, Germany. This conference aimed to solve practical and controversial issues surrounding the implementation of the European Guidelines in Germany. To this end, a number of working groups was initiated, one of which was specifically dedicated to the clinical classification and initial diagnosis of PH. This article summarizes the results and recommendations of this working group.
Subject(s)
Blood Pressure Determination/standards , Cardiology/standards , Hypertension, Pulmonary/diagnosis , Practice Guidelines as Topic , Pulmonary Medicine/standards , Terminology as Topic , Early Diagnosis , Germany , Humans , Hypertension, Pulmonary/classificationABSTRACT
The 2015 European Guidelines on Diagnosis and Treatment of Pulmonary Hypertension are also valid for Germany. The guidelines contain detailed recommendations for the targeted treatment of pulmonary arterial hypertension (PAH). However, the practical implementation of the European Guidelines in Germany requires the consideration of several country-specific issues and already existing novel data. This requires a detailed commentary to the guidelines, and in some aspects an update already appears necessary. In June 2016, a Consensus Conference organized by the PH working groups of the German Society of Cardiology (DGK), the German Society of Respiratory Medicine (DGP) and the German Society of Pediatric Cardiology (DGPK) was held in Cologne, Germany. This conference aimed to solve practical and controversial issues surrounding the implementation of the European Guidelines in Germany. To this end, a number of working groups was initiated, one of which was specifically dedicated to the management of decompensated right heart failure, intensive care management and perioperative management in patients with pulmonary hypertension. This article summarizes the results and recommendations of the working group on decompensated right heart failure, intensive care and perioperative management in patients with pulmonary hypertension.
Subject(s)
Cardiology/standards , Hypertension, Pulmonary/surgery , Monitoring, Intraoperative/standards , Practice Guidelines as Topic , Pulmonary Medicine/standards , Ventricular Dysfunction, Right/prevention & control , Germany , Humans , Hypertension, Pulmonary/complications , Hypertension, Pulmonary/diagnosis , Ventricular Dysfunction, Right/diagnosis , Ventricular Dysfunction, Right/etiologyABSTRACT
The 2015 European Guidelines on Pulmonary Hypertension did not cover only pulmonary arterial hypertension (PAH), but also other significant subgroups of pulmonary hypertension (PH). In June 2016, a Consensus Conference organized by the PH working groups of the German Society of Cardiology (DGK), the German Society of Respiratory Medicine (DGP) and the German Society of Pediatric Cardiology (DGPK) was held in Cologne, Germany to discuss open and controversial issues surrounding the practical implementation of the European Guidelines. Several working groups were initiated, one of which was dedicated to the diagnosis and treatment of chronic thromboembolic pulmonary hypertension (CTEPH). In every patient with PH of unknown cause CTEPH should be excluded. The primary treatment option is surgical pulmonary endarterectomy (PEA) in a specialized multidisciplinary CTEPH center. Inoperable patients or patients with persistent or recurrent CTEPH after PEA are candidates for targeted drug therapy. For balloon pulmonary angioplasty (BPA), there is currently only limited experience. This option - as PEA - is reserved to specialized centers with expertise for this treatment method. In addition, a brief overview is given on pulmonary artery sarcoma, since its surgical treatment is often analogous to PEA. The recommendations of this working group are summarized in the present paper.
Subject(s)
Hypertension, Pulmonary/diagnosis , Hypertension, Pulmonary/therapy , Practice Guidelines as Topic , Pulmonary Embolism/diagnosis , Pulmonary Embolism/therapy , Pulmonary Medicine/standards , Antihypertensive Agents/administration & dosage , Cardiology/standards , Drug Therapy, Combination/standards , Fibrinolytic Agents/administration & dosage , Humans , Hypertension, Pulmonary/etiology , Molecular Targeted Therapy/standards , Pulmonary Embolism/complicationsABSTRACT
BACKGROUND: Patients with pulmonary hypertension (PH) are at high risk when undergoing surgery. Up to one-third of patients suffer complications; recent studies report a mortality rate of 1 to 7%. Frequent events are deterioration of right heart function and infectious or bleeding complications. METHODS: Data of patients (age ≥ 18) with precapillary PH who need to undergo elective surgery between January 2006 and March 2015 were included in this retrospective analysis. All patients who were planned for surgery underwent the same procedure. First, patients were evaluated in the PH center. Thereafter, PH-relevant data were discussed with the surgeon/anesthesiologist team for risk-adapted planning of anesthesia and intervention. The present analysis comprises patient characteristics and information about surgery and post-interventional course. RESULTS: This study analyzes 31 surgical procedures carried out in PH patients (male: n = 8; PH-group I: n = 23, group III: n = 3, group IV: n = 5, mean age: 59.5 ± 15.3 years). Patients were characterized by compromised hemodynamics and exercise capacity: pulmonary vascular resistance: 805.4 ± 328.5 dyn*s*cm(-5), mean pulmonary arterial pressure: 46.3 ± 9.3 mmHg, 6-minute walking distance: 350.3 ± 123.3 m.The majority of interventions were performed under general anesthesia (n = 24). In 25 cases, the intraoperative monitoring was complemented with right heart catheterization.Eight interventions were associated with complications, three of which were serious. One patient died postoperatively owing to sepsis and right heart failure. CONCLUSION: A careful and structured planning of surgical interventions in patients with PH and the choice of surgical procedure and anesthesia adapted to the conditions of PH might help avoid complications. Further multicentric studies are needed.
Subject(s)
Hypertension, Pulmonary/mortality , Hypertension, Pulmonary/surgery , Postoperative Complications/mortality , Postoperative Complications/prevention & control , Vascular Surgical Procedures/mortality , Vascular Surgical Procedures/statistics & numerical data , Adult , Aged , Aged, 80 and over , Female , Germany , Humans , Hypertension, Pulmonary/diagnosis , Male , Middle Aged , Postoperative Complications/diagnosis , Retrospective Studies , Survival Rate , Treatment OutcomeABSTRACT
Dyspnoea is the predominant symptom in patients with pulmonary hypertension (PH) at diagnosis. However, since dyspnoea is nonspecific and often occurs in a number of common diseases, the presence of PH can easily be underdiagnosed.In addition, this symptom underlies a high variability in the subjective perception, therefore further diagnostic procedures are often delayed by the patients.A survey of the incidence and severity of dyspnoea in 372 patients with PAH was conducted by questionnaire in German centres. Age, sex distribution and the range of comorbidities corresponded to the findings of national and international registries.Approximately 99â% of patients reported the presence of dyspnoea on exertion, even at low loads.Remarkably, in 13â% of patients dyspnoea occurs as a paroxysmal symptom, which may lead to the differential diagnosis of bronchial asthma. In addition, the patients who were being followed in specialized PH centres reported an increase in dyspnoea during the last year.The results of the survey on the incidence of dyspnoea in patients with PAH are consistent with the findings of international studies.
Subject(s)
Dyspnea/diagnosis , Dyspnea/epidemiology , Hypertension, Pulmonary/diagnosis , Hypertension, Pulmonary/epidemiology , Adult , Age Distribution , Aged , Aged, 80 and over , Comorbidity , Female , Germany/epidemiology , Health Care Surveys , Humans , Incidence , Male , Middle Aged , Respiratory Care Units/statistics & numerical data , Respiratory Center , Risk Assessment , Sex Distribution , Young AdultABSTRACT
Pulmonary arterial hypertension (PAH) is associated with a change in vascular architecture. A characteristic histological feature is the plexiform lesion. Similar alterations are observed in the pulmonary vascular bed of patients with chronic thromboembolic pulmonary hypertension (CTEPH). Cytokines involved in angiogenesis were found in both serum and lung tissue of patients with PAH and CTEPH, although their role in the formation of plexiform lesions remains unclear. The examination of breath condensate is a noninvasive technique to analyse proteins possibly associated with the pathogenesis of various lung diseases.Breath condensate of 22 patients with pulmonary hypertension (PAH: nâ=â12; CTEPH: nâ=â10) and 7 healthy volunteers was examined using a multiplex fluorescent bead immunoassay to determine the concentrations of the biomarkers angiogenin, bFGF, VEGF, IL-8, and TNF-α. Significantly higher levels of angiogenin, bFGF and TNF-α were observed in breath condensate of patients with pulmonary hypertension in comparison to healthy controls. Similarly, breath condensate levels of VEGF were elevated in patients with PAH as against healthy volunteers. However, IL-8 levels in breath condensate did not differ between the two groups. The data suggest that breath condensate of patients with pulmonary hypertension is characterized by increased levels of the angiogenic factors angiogenin, VEGF and bFGF as well as TNF-α, but not IL-8. A larger study is needed to confirm these results and to determine the prognostic and therapeutic implications of these findings.
Subject(s)
Breath Tests/methods , Fibroblast Growth Factor 2/analysis , Hypertension, Pulmonary/diagnosis , Neovascularization, Pathologic/diagnosis , Ribonuclease, Pancreatic/analysis , Vascular Endothelial Growth Factor A/analysis , Biomarkers/analysis , Female , Humans , Hypertension, Pulmonary/complications , Hypertension, Pulmonary/metabolism , Male , Middle Aged , Neovascularization, Pathologic/etiology , Neovascularization, Pathologic/metabolism , Reproducibility of Results , Sensitivity and SpecificityABSTRACT
Acupuncture, a subsection of traditional Chinese medicine, plays an important role as an alternative healing method. Even though there is little proof of its efficacy, acupuncture is becoming more and more popular in the Western world, especially because it is considered almost free of side effects. However, severe complications may occur and have previously been described.We will present a patient who suffered from bilateral pneumothoraces after acupuncture into the paravertebral area. This complication was not considered as a differential diagnosis thus even worsening the patient's life-threatening condition.
Subject(s)
Acupuncture Therapy/adverse effects , Pneumothorax/diagnosis , Pneumothorax/etiology , Diagnosis, Differential , False Negative Reactions , Female , Humans , Middle Aged , Myocardial Infarction/diagnosis , Myocardial Infarction/etiology , Myocardial Infarction/therapy , Pneumothorax/therapy , Pulmonary Disease, Chronic Obstructive/diagnosis , Pulmonary Disease, Chronic Obstructive/etiology , Pulmonary Disease, Chronic Obstructive/therapy , Treatment OutcomeSubject(s)
Hypertension, Pulmonary/diagnosis , Hypertension, Pulmonary/therapy , Pulmonary Embolism/diagnosis , Pulmonary Embolism/therapy , Angioplasty, Balloon , Anticoagulants/administration & dosage , Chronic Disease , Endarterectomy , Follow-Up Studies , Humans , Hypertension, Pulmonary/mortality , Long-Term Care , Pulmonary Embolism/mortality , Survival RateABSTRACT
This position paper summarises current developments in chronic thromboembolic pulmonary hypertension (CTEPH) including diagnostic approaches and treatment options. Based on the guidelines of the task force of CTEPH experts at the 5th World Symposium on Pulmonary Hypertension in Nice 2013. Open questions arising during the treatment of patients with CTEPH are addressed. Patients with suspected CTEPH should undergo echocardiography and cardiopulmonary exercise testing. A ventilation/perfusion scan is the recommended imaging test for screening in the diagnostic algorithm for the evaluation of CTEPH. CTEPH-patients should be discussed in an expert center with an interdisciplinary team and an experienced PEA surgeon to decide the further treatment. Pulmonary endarterectomy (PEA) is the treatment of choice for patients with CTEPH. Medical therapy with PH-targeted medications for inoperable CTEPH and residual disease after PEA should only be initiated if evaluation reveals that the patient is no candidate for a PEA. Current data suggest that CTEPH patients treated with PEA have a better long-term survival rate and quality of life than patients treated with medical therapy.
Subject(s)
Hypertension, Pulmonary/diagnosis , Hypertension, Pulmonary/therapy , Pulmonary Embolism/diagnosis , Pulmonary Embolism/therapy , Algorithms , Chronic Disease , Combined Modality Therapy , Cooperative Behavior , Echocardiography , Endarterectomy , Exercise Test , Humans , Hypertension, Pulmonary/mortality , Hypertension, Pulmonary/physiopathology , Interdisciplinary Communication , Mass Screening , Molecular Targeted Therapy , Practice Guidelines as Topic , Prognosis , Pulmonary Artery , Pulmonary Embolism/mortality , Pulmonary Embolism/physiopathology , Survival Rate , Tertiary Care Centers , Ventilation-Perfusion Ratio/physiologyABSTRACT
INTRODUCTION: Ambrisentan, a selective endothelin receptor antagonist has been approved in several countries for pulmonary arterial hypertension. No data have been published on the efficacy of ambrisentan on improvement of exercise capacity in patients with portopulmonary hypertension (PoPH). PATIENTS AND METHODS: We retrospectively analyzed the safety and efficacy of ambrisentan in patients with PoPH in four German university hospitals. RESULTS: 14 patients with moderate to severe PoPH were included. The median follow-up was 16 months (IQR, 12 - 21). 6 minute walk tests after 6 and 12 months improved from 376 meters (IQR, 207 - 440) at baseline to 415 meters (IQR, 393 - 475; p = 0.011) and 413 meters (IQR, 362 - 473, p = 0.005), respectively. WHO- functional class after 1 year of therapy with ambrisentan also improved significantly (p = 0.014). No significant changes in blood gas analysis and liver function tests (aspartate aminotransferase, alanine aminotransferase, total bilirubin, and international normalized ratio) during therapy with ambrisentan were detectable. CONCLUSIONS: The present study demonstrates significant improvement of exercise capacity and clinical symptoms without relevant safety concerns during ambrisentan treatment in patients with PoPH.
Subject(s)
Antihypertensive Agents/pharmacology , Exercise , Hypertension, Pulmonary , Phenylpropionates/pharmacology , Pyridazines/pharmacology , Antihypertensive Agents/therapeutic use , Dose-Response Relationship, Drug , Exercise Test , Follow-Up Studies , Humans , Hypertension, Pulmonary/drug therapy , Hypertension, Pulmonary/physiopathology , Phenylpropionates/therapeutic use , Pyridazines/therapeutic use , Retrospective Studies , Treatment OutcomeABSTRACT
In the 2009 European Guidelines on pulmonary hypertension one section covers aspects of pathophysiology, diagnosis and treatment of chronic thromboembolic pulmonary hypertension (CTEPH). The practical implementation of the guidelines for this disease is of crucial importance, because CTEPH is a form of pulmonary hypertension which can be surgically cured. It is, however, frequently diagnosed late in the course of disease and often treated not correctly. In the European Guidelines CTEPH is addressed relatively briefly, although it is a common form of PH which is often overlooked. Any patient with unexplained PH should be evaluated for the presence of CTEPH. A ventilation/perfusion lung scan is recommended as the first step to exclude CTEPH. If the ventilation/perfusion lung scan or multislice CT angiography reveals perfusions defects suggesting the diagnosis of CTEPH, the patient should be referred to a centre with expertise in the medical and surgical management of these patients. After diagnosis of CTEPH the case has to be reviewed by an experienced surgeon in a PEA centre for assessment of operability. The recommendations of the European guidelines are summarized in the current manuscript with additional comments regarding diagnosis and treatment according to most recent evidence.
Subject(s)
Hypertension, Pulmonary/physiopathology , Pulmonary Embolism/physiopathology , Angiography , Chronic Disease , Delayed Diagnosis , Germany , Hemodynamics/physiology , Humans , Hypertension, Pulmonary/diagnosis , Hypertension, Pulmonary/surgery , Prognosis , Pulmonary Embolism/diagnosis , Pulmonary Embolism/surgery , Tomography, Spiral Computed , Ventilation-Perfusion Ratio/physiologyABSTRACT
Lymphomatoid granulomatosis (LYG) is a rare disease with an unknown pathogenesis. It is considered as a B-cell disorder with an uncertain malignant potential. The disease is classified as an angiocentric and angiodestructive lymphoproliferative disorder. EBV-association (LMP1) and the detection of the surface antigens CD20 and CD30 are the characteristic pathological findings. The lung, the nervous system, the kidneys and the liver are affected most frequently. In the present report the case of a 79-year-old man is described, who showed a cavity in the upper right lobe which was opened out into the trachea. The initial CXR and CT scan demonstrated a large nodular air space opacity (reversed halo sign) on the upper right area and a smaller one on the left side. In addition to CT and bronchoscopy, a surgical biopsy was performed to confirm the diagnosis of lymphomatoid granulomatosis. Treatment consisted in chemotherapy with rituximab, cyclophosphamide, vincristine and prednisolone (R-CVP). Three months after confirmation of diagnosis the patient died of an abscess-forming pneumonia.
Subject(s)
Lung Diseases/diagnosis , Lung Diseases/therapy , Lymphomatoid Granulomatosis/diagnosis , Lymphomatoid Granulomatosis/therapy , Aged , Humans , Male , Rare Diseases/diagnosis , Rare Diseases/therapyABSTRACT
There is limited data on the long-term efficacy of intravenous iloprost in patients with pulmonary arterial hypertension (PAH). This retrospective multicentre analysis evaluated the clinical course of patients with PAH treated with i.v. iloprost, in most cases after having received inhaled iloprost as first-line therapy. Between 1997 and 2001, 79 PAH patients were treated with i.v. iloprost and followed until 2007. These patients had advanced and progressive disease as indicated by a mean pulmonary vascular resistance of 1,533 dyn x s x cm(-5) at the time of diagnosis and of 1,858 dyn x s x cm(-5) at the onset of i.v. iloprost therapy. Introduction of i.v. iloprost therapy resulted in initial haemodynamic and clinical improvement. At the end of the observation period, however, 50 (61%) patients had died and 21 (26%) required lung transplantation. Transplantation-free survival rates at 1, 3, and 5 yrs were 86%, 59% and 45%, respectively, after the diagnosis of PAH, and 54%, 31% and 15%, respectively, after the introduction of i.v. iloprost therapy. Predictors of an adverse outcome at baseline were a low 6-min walk distance and a low mixed venous oxygen saturation. In conclusion, despite initial haemodynamic and clinical improvement, overall long-term survival with i.v. iloprost therapy was limited.
